Crescent Biopharma (CBIO) has priced an underwritten offering of about 8.1 million common shares and, for certain investors, pre-funded warrants to purchase up to 525,897 common shares at $14.50 each, the cancer-treatment company said late Tuesday.
Underwriters have been granted a 30-day option to purchase up to about 1.3 million additional shares.
Crescent Biopharma expects to raise $125 million from the offering, which is slated to close Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments